Authors

Odysseas Gregoriou, M.D., Panagiotis Bakas, M.D., Charalampos Grigoriadis, M.D., Maria Creatsa, M.D., Dimitrios Hassiakos, M.D., Georgios Creatsas, M.D.

Vol 98, Issue 1 , Pages 48-51

Abstract

Objective:

To compare the effects of 2.5 mg letrozole with those of 1 mg anastrazole daily on the hormonal and semen profiles of a subset of infertile men with low T/E2 ratios.

Design:

Prospective, nonrandomized study.

Setting:

Reproductive medicine clinic.

Patient(s):

The study group consisted of 29 infertile men with a low serum T/E2 ratio (<10).

Intervention(s):

Patients were divided into two groups. Group A included 15 patients treated with 2.5 mg letrozole orally once daily for 6 months, and Group B consisted of 14 patients treated with 1 mg anastrazole orally every day for 6 months.

Main Outcome Measure(s):

Hormonal evaluation included measurement of serum FSH, LH, PRL, T, and E2. In all sperm analyses pretreatment and posttreatment total motile sperm counts (ejaculate volume × concentration × motile fraction) were evaluated.

Result(s):

The use of aromatase inhibitors (either letrozole or anastrazole) in cases of infertile men with low T/E2 ratios improved both hormonal and semen parameters.

Conclusion(s):

This study suggests that some men with severe oligospermia, low T levels, and normal gonadotropin concentration may have a treatable endocrinopathy.

Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00436-0/fulltext